Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mundipharma Laboratories and its independent associated firm Purdue Pharmaceuticals have entered into global multi-program discovery and development collaboration with Laboratorios Esteve to develop new pain management products.
Subscribe to our email newsletter
As part of the deal, Mundipharma and Purdue could make payments in excess of $1bn to Esteve if all development, regulatory and sales milestones are met across the different programs.
The deals combines Mundipharma’s and Purdue’s commitment to the development and commercialization of new pain treatments together with Esteve’s pain focused research and development expertise, particularly in the field of sigma-1 receptor biology.
The collaboration covers E-52862, a first-in-class new chemical entity targeting the sigma-1 receptor pathway, which is currently being evaluated in Phase II trials for multiple neuropathic pain indications.
The deal also offers access to lead asset of Esteve’s Multi-Modal (MuMo) technology platform MuMo-1, which is currently in preclinical development with the potential to improve sigma-1 asset properties through the introduction of additional characteristics that are tailored for specific disease states.
Under the agreement, Mundipharma and Purdue will have primary commercial rights for this asset and Esteve retains rights in certain territories.
It also includes E-58425, a new first-in-class patented API:API co-crystal of tramadol and celecoxib, which leverages the efficacy properties of both compounds while lowering the component dosages and associated adverse effects.
In addition to existing expertise in opioids and severe pain, the partnership will see Mundipharma and Purdue expand their pain franchise into neuropathic, acute and moderate pain.